BioCentury
ARTICLE | Clinical News

Genocea discontinues HSV-2 candidate GEN-003

September 29, 2017 9:35 PM UTC

Genocea Biosciences Inc. (NASDAQ:GNCA) said it is "exploring strategic alternatives" and ceasing development of GEN-003, which has completed Phase II testing to treat genital herpes simplex virus type 2 (HSV-2) infection. The company will reduce headcount by 40%, and expects an annual savings of $6.5 million.

The T cell vaccine consists of the infected cell polypeptide 4 (ICP4) and gD2 antigens from herpes simplex virus-2 (HSV-2) combined with the saponin-derivative adjuvant Matrix-M2...

BCIQ Company Profiles

Genocea Biosciences Inc.